Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B Patients

• Published in: Hepatology (Baltimore, Md.) Vol. 73; no. 1; pp. 41 - 52
• Main Authors: Huang, Qi, Zhou, Bin, Cai, Dawei, Zong, Yuhua, Wu, Yaobo, Liu, Shi, Mercier, Alexandre, Guo, Haitao, Hou, Jinlin, Colonno, Richard, Sun, Jian
• Format: Journal Article
• Language: English
• Published: United States John Wiley and Sons Inc 01.01.2021
• Subjects: Adolescent; Adult; Aged; Antiviral Agents - therapeutic use; Biomarkers - blood; DNA, Circular - drug effects; DNA, Viral - blood; DNA, Viral - drug effects; Female; Hepatitis B Core Antigens - blood; Hepatitis B e Antigens - blood; Hepatitis B virus - drug effects; Hepatitis B virus - genetics; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - genetics; Hepatitis B, Chronic - virology; Humans; Lamivudine - therapeutic use; Liver - drug effects; Liver - virology; Male; Middle Aged; Mutation; Original; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult

Background and Aims Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) plays a pivotal role in the establishment and persistence of HBV infection. Understanding the turnover time of preexisting cccDNA pools would be helpful in designing strategies to clear HBV by fully blocking the de n...